Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Srdan Verstovsek
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Cell Therapeutics; Geron; Gilead Sciences; Incyte; Lilly; Novartis; NS Pharma; Promedior
Ruben A. Mesa
Research Funding - Genentech; Incyte; Promedior
Lynda M. Foltz
Research Funding - Promedior
Vikas Gupta
Consultant or Advisory Role - Incyte; Novartis
Honoraria - Incyte; Novartis
Research Funding - Incyte; Novartis; Promedior
John Mascarenhas
Research Funding - Incyte; Novartis
Ellen K. Ritchie
Research Funding - Novartis; Promedior; Sanofi
Ronald Hoffman
Research Funding - Incyte; Novartis; Promedior
Richard T. Silver
Research Funding - Incyte; Novartis; Promedior
Wan-Jen Hong
No relevant relationships to disclose
Marina Kremyanskaya
No relevant relationships to disclose
Elizabeth G. Trehu
Employment or Leadership Position - Promedior
Stock Ownership - Promedior
Hagop M. Kantarjian
No relevant relationships to disclose
Jason R. Gotlib
Research Funding - Incyte; Sanofi